Patterns of diagnostic marker assessment in adult diffuse glioma: “Adelheid Wöhrer et al. present the results of a Euro-CNS survey on patterns of diagnostic marker assessment in diffuse glioma. This Euro-CNS survey is the first of its kind and shall set a baseline for future follow-up surveys. A total of 130 colleagues engaged in brain tumor diagnostics from 40 nations participated, including also representatives from a number of countries outside of Europe. The main aim of the survey was to assess the translational status of diagnostic molecular marker testing in diffuse gliomas after release of the WHO 2016 brain tumor classification. The WHO 2016 classification has introduced for the first time an integrated diagnostic approach incorporating both tumor morphology and molecular information. The responses show that molecular marker testing is uniformly considered as highly relevant, and in most centers, molecular information is incorporated already in diagnostic assessments. However, there are substantial differences in access to molecular markers and techniques, and there is also a high level of heterogeneity of methods and platforms used for testing, even within the same countries. Further, the respondents express a high level of concern with regard to validity of test assays and advocate the need for international harmonization of standards and consensus guidelines. The majority expressed willingness to actively engage in interlaboratory trials aiming at quality control. Euro-CNS could serve in future as platform in the development of such international trials within Europe and beyond.” Quoted from the Editorial by Johannes Hainfellner in Clinical Neuropathology 2017-1. For the published results of the survey click here.